Sponsor & Developer Portfolio
Murdoch Childrens Research Institute
Clinical development pipeline, platform architecture, and registered trial tracking for Murdoch Childrens Research Institute vaccine candidates.
2
Candidates
1
Target Diseases
2
Linked Studies
Development Phase Distribution
Phase 3 Clinical Trial: 1 Discontinued / Inactive: 1
Platform Technologies
Biological (unspecified platform): 2
Target Pathogens & Indications
COVID-19
Vaccine Pipeline Candidates (2)
Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.
Discontinued / Inactive
ctgov-pfizer-biontech-standard-dose-murdoch-childrens-research-institu
AstraZeneca Standard dose
Target: COVID-19
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2025-01 (registry estimate)
Phase 3 Clinical Trial
ctgov-bivalent-moderna-murdoch-childrens-research-institute
Novavax
Target: COVID-19
Platform: Biological (unspecified platform)
Key Milestone: Primary completion (most advanced trial): 2024-10-13 (registry estimate)
Explore Other Vaccine Developers & Sponsors
Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.